ARAY
Price
$1.42
Change
+$0.03 (+2.16%)
Updated
Jul 3 closing price
Capitalization
244.95M
40 days until earnings call
NSPR
Price
$2.24
Change
+$0.01 (+0.45%)
Updated
Jul 3 closing price
Capitalization
55.59M
38 days until earnings call
Interact to see
Advertisement

ARAY vs NSPR

Header iconARAY vs NSPR Comparison
Open Charts ARAY vs NSPRBanner chart's image
Accuray
Price$1.42
Change+$0.03 (+2.16%)
Volume$486.93K
Capitalization244.95M
InspireMD
Price$2.24
Change+$0.01 (+0.45%)
Volume$44.76K
Capitalization55.59M
ARAY vs NSPR Comparison Chart in %
Loading...
ARAY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NSPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARAY vs. NSPR commentary
Jul 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARAY is a Hold and NSPR is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 05, 2025
Stock price -- (ARAY: $1.42 vs. NSPR: $2.24)
Brand notoriety: ARAY and NSPR are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: ARAY: 49% vs. NSPR: 24%
Market capitalization -- ARAY: $244.95M vs. NSPR: $55.59M
ARAY [@Medical Specialties] is valued at $244.95M. NSPR’s [@Medical Specialties] market capitalization is $55.59M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARAY’s FA Score shows that 0 FA rating(s) are green whileNSPR’s FA Score has 0 green FA rating(s).

  • ARAY’s FA Score: 0 green, 5 red.
  • NSPR’s FA Score: 0 green, 5 red.
According to our system of comparison, both ARAY and NSPR are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARAY’s TA Score shows that 4 TA indicator(s) are bullish while NSPR’s TA Score has 3 bullish TA indicator(s).

  • ARAY’s TA Score: 4 bullish, 4 bearish.
  • NSPR’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, ARAY is a better buy in the short-term than NSPR.

Price Growth

ARAY (@Medical Specialties) experienced а +7.58% price change this week, while NSPR (@Medical Specialties) price change was -0.88% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +1.95%. For the same industry, the average monthly price growth was +1.48%, and the average quarterly price growth was -0.02%.

Reported Earning Dates

ARAY is expected to report earnings on Aug 14, 2025.

NSPR is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Medical Specialties (+1.95% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARAY($245M) has a higher market cap than NSPR($55.6M). NSPR YTD gains are higher at: -14.829 vs. ARAY (-28.283). ARAY has higher annual earnings (EBITDA): 5.93M vs. NSPR (-20.91M). ARAY has more cash in the bank: 72.8M vs. NSPR (39M). NSPR has less debt than ARAY: NSPR (1.6M) vs ARAY (202M). ARAY has higher revenues than NSPR: ARAY (447M) vs NSPR (6.21M).
ARAYNSPRARAY / NSPR
Capitalization245M55.6M441%
EBITDA5.93M-20.91M-28%
Gain YTD-28.283-14.829191%
P/E RatioN/AN/A-
Revenue447M6.21M7,204%
Total Cash72.8M39M187%
Total Debt202M1.6M12,665%
FUNDAMENTALS RATINGS
ARAY vs NSPR: Fundamental Ratings
ARAY
NSPR
OUTLOOK RATING
1..100
121
VALUATION
overvalued / fair valued / undervalued
1..100
86
Overvalued
37
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
8898
PRICE GROWTH RATING
1..100
8484
P/E GROWTH RATING
1..100
50100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NSPR's Valuation (37) in the Medical Specialties industry is somewhat better than the same rating for ARAY (86). This means that NSPR’s stock grew somewhat faster than ARAY’s over the last 12 months.

NSPR's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as ARAY (100). This means that NSPR’s stock grew similarly to ARAY’s over the last 12 months.

ARAY's SMR Rating (88) in the Medical Specialties industry is in the same range as NSPR (98). This means that ARAY’s stock grew similarly to NSPR’s over the last 12 months.

ARAY's Price Growth Rating (84) in the Medical Specialties industry is in the same range as NSPR (84). This means that ARAY’s stock grew similarly to NSPR’s over the last 12 months.

ARAY's P/E Growth Rating (50) in the Medical Specialties industry is somewhat better than the same rating for NSPR (100). This means that ARAY’s stock grew somewhat faster than NSPR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARAYNSPR
RSI
ODDS (%)
Bullish Trend 3 days ago
71%
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
82%
Bullish Trend 3 days ago
80%
Momentum
ODDS (%)
Bullish Trend 3 days ago
75%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bullish Trend 3 days ago
77%
Bearish Trend 3 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 3 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
82%
Bearish Trend 3 days ago
88%
Advances
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 9 days ago
79%
Declines
ODDS (%)
N/A
N/A
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
82%
Bullish Trend 3 days ago
90%
Aroon
ODDS (%)
N/A
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ARAY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NSPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
EBRGF13.55N/A
N/A
Enbridge Inc.
HTSUY6.75N/A
N/A
Hisamitsu Pharmaceutical Co., Ltd.
BRIBF0.26N/A
N/A
BRII BIOSCIENCE LTD
OSCUF9.75-1.65
-14.47%
Japan Exchange Group, Inc.
ALDVF0.21-0.06
-22.51%
KIPLIN METALS INC.

ARAY and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARAY has been loosely correlated with KIDS. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ARAY jumps, then KIDS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARAY
1D Price
Change %
ARAY100%
+2.16%
KIDS - ARAY
44%
Loosely correlated
+1.54%
ILMN - ARAY
44%
Loosely correlated
+0.46%
A - ARAY
42%
Loosely correlated
+0.60%
ALGN - ARAY
42%
Loosely correlated
-0.08%
NVST - ARAY
41%
Loosely correlated
+1.09%
More

NSPR and

Correlation & Price change

A.I.dvisor tells us that NSPR and VCYT have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NSPR and VCYT's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NSPR
1D Price
Change %
NSPR100%
+0.45%
VCYT - NSPR
22%
Poorly correlated
-0.25%
ARAY - NSPR
22%
Poorly correlated
+2.16%
POAI - NSPR
22%
Poorly correlated
+1.89%
LUNG - NSPR
21%
Poorly correlated
+2.21%
NNOX - NSPR
21%
Poorly correlated
-0.19%
More